Eli Lilly Collaborates with Advancell on Cancer Therapies, $2.5 Billion Acquisition of Scorpion Drug, Files for Notes Offering

Eli Lilly has entered into a strategic collaboration with Advancell to advance novel targeted alpha therapies aimed at cancer treatment. In addition, Eli Lilly is preparing to tap the U.S. investment-grade bond market to finance its approximately $2.5 billion acquisition of a cancer drug from Scorpion Therapeutics. The company is also seeking to expand its operations into cancer radiopharmaceuticals and fatty liver disease through two global deals. Furthermore, Eli Lilly has filed for a six-part notes offering, although the size of this offering has not been disclosed.